Immunological studies and in vitro schistosomicide action of new imidazolidine derivatives
J. venom. anim. toxins incl. trop. dis
;
17(3): 277-286, 2011. graf, tab
Article
Dans Anglais
| LILACS
| ID: lil-597226
ABSTRACT
Schistosomiasis is a major public health problem with 207 million people infected and more than 779 million at risk. The drug of choice for treating schistosomiasis is praziquantel (PZQ); however, it is inefficient against immature forms of schistosomes. The aim of this study was to test new imidazolidine derivatives LPSF/PT09 and LPSF/PT10 against adult Schistosoma mansoni worms. IC50, cytotoxicity, immune response and cell viability assays were also available for these imidazolidines. Different concentrations of imidazolidine, from 32 to 320 »M, promoted motor abnormalities in breeding and unpaired worms, and death in 24 hours at higher concentrations. Although LPSF/PT09 and LPSF/PT10 did not affect IFN-³ and IL-10 production, they induced nitric oxide production and showed a similar behavior to praziquantel on cell death test. Thus, these new imidazolidine derivatives should undergo further study to develop schistosomiasis drugs.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Schistosoma mansoni
/
Imidazolidines
Limites du sujet:
Animaux
langue:
Anglais
Texte intégral:
J. venom. anim. toxins incl. trop. dis
Thème du journal:
Toxicologie
Année:
2011
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Federal University of Pernambuco/BR
/
Oswaldo Cruz Foundation/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS